Mesenchymal Lesions of the Vulva and Vagina


Introduction

Mesenchymal lesions that occur in the vulva and vagina can be separated into two general categories: (1) those that are relatively site-specific, i.e., they may occasionally occur at extragenital sites; and (2) those that occur more commonly at other sites but which may also involve this region. The former group is described in detail in this chapter. Most entities in the latter group have the same clinical and pathologic characteristics as their extragenital counterparts, with exception of vulvovaginal smooth muscle tumors which have site-specific diagnostic criteria (and thus are also covered here). Certain entities important in the differential diagnosis are also discussed.

Fibroepithelial Stromal Polyp

Clinical Features

Fibroepithelial stromal polyps are common in women of reproductive age (most commonly during pregnancy) but may be seen in postmenopausal women on hormonal replacement therapy. They are often incidental findings discovered during routine gynecologic examination. Symptoms, when present, may include bleeding, discharge, or the sensation of a mass. Fibroepithelial polyps usually present as a solitary lesion; however, multiple polyps may occur during pregnancy, after which they typically regress.

Pathologic Features

Gross Findings

The lesion is usually <5 cm, polypoid or pedunculated, and may project from a thin connecting stalk. Occasionally, they may have multiple finger-like projections, which can mimic a condyloma.

Microscopic Findings

Fibroepithelial stromal polyps are exophytic lesions with a variably cellular stroma, central fibrovascular core, and overlying squamous epithelium. The most characteristic feature is the presence of stellate and multinucleate stromal cells, which are most commonly seen near the epithelial–stromal interface or adjacent to the prominent central vasculature ( Fig. 4.1 ). Sometimes the lesion displays high stromal cellularity, nuclear pleomorphism, and mitotic activity (including >10 mitoses/10 high power fields [HPFs] and atypical mitoses), thereby mimicking a sarcoma ( Fig. 4.2 ). Importantly, there is no clearly defined margin or sharp demarcation from the epithelial–stromal interface (absence of cambium layer).

FIG. 4.1, Fibroepithelial stromal polyp. Characteristic stellate and multinucleated stromal cells are prominent near the stromal–epithelial interface.

FIG. 4.2, Fibroepithelial stromal polyp. Increased stromal cellularity and atypia are seen. Note the presence of the characteristic multinucleated cells.

Ancillary Studies

Immunohistochemistry

The stromal cells of these lesions are often positive for desmin, vimentin, and estrogen and progesterone receptors (ER and PR), and less frequently for actin. RB1 expression is intact.

Differential Diagnosis

Fibroepithelial stromal polyps, particularly those with increased cellularity and atypical stromal cells, must be distinguished from a malignant process. Sarcomas typically have an identifiable lesional margin, show homogeneous cellularity throughout, and lack the stellate and multinucleate stromal cells near the epithelial–stromal interface. In contrast, even the most floridly pseudosarcomatous examples of fibroepithelial stromal polyps characteristically show stellate multinucleated cells and tend to exhibit a greater degree of cellularity in the center of the lesion. Fibroepithelial stromal polyps are readily distinguished from botryoid embryonal rhabdomyosarcoma , as fibroepithelial stromal polyps are rare before puberty and lack the characteristic hypercellular subepithelial (cambium) layer and specific markers of skeletal muscle differentiation. When stromal polyps are edematous, a deep (aggressive) angiomyxoma may be considered; however, the latter is typically more deeply located, is uniformly hypocellular, has myxoid instead of edematous stroma, and lacks stellate and multinucleate cells.

Prognosis and Therapy

These lesions have the potential to recur locally, particularly if incompletely excised or if there is continued hormonal stimulation (e.g., pregnancy).

Fibroepithelial Stromal Polyp—Fact Sheet

Definition

  • □n

    Benign polypoid growth that arises from distinctive subepithelial stroma of distal female genital tract

Incidence and Location

  • □n

    Most common during pregnancy

  • □n

    May occur in vulva, vagina, and, rarely, cervix

Morbidity and Mortality

  • □n

    If large, may cause pain and bleeding

Gender, Race, and Age Distribution

  • □n

    Typically reproductive-aged women

  • □n

    May occur in postmenopausal women on hormone replacement therapy

  • □n

    There is an association with pregnancy

Clinical Features

  • □n

    Typically polypoid or pedunculated with thin connecting stalk

  • □n

    Multiple polyps may occur during pregnancy

Prognosis and Treatment

  • □n

    Benign lesion; may regress (following pregnancy)

  • □n

    Complete local excision treatment of choice

  • □n

    Potential for local recurrence if incompletely excised or if continued hormonal stimulation

Fibroepithelial Stromal Polyp—Pathologic Features

Gross Findings

  • □n

    Usually <5 cm

  • □n

    Polypoid or pedunculated with thin connecting stalk

Microscopic Findings

  • □n

    Polypoid with variably cellular stroma, central fibrovascular core, and overlying squamous epithelium

  • □n

    Stellate and multinucleate stromal cells are characteristic; typically located at the epithelial–stromal interface and around blood vessels

  • □n

    Some polyps may exhibit stromal hypercellularity, stromal cell nuclear pleomorphism, and increased mitotic activity (so-called pseudosarcoma botryoides)

Immunohistochemical Findings

  • □n

    Desmin, vimentin, ER, and PR typically positive

  • □n

    Actin less frequently positive

  • □n

    Intact RB1 expression

Differential Diagnosis

  • □n

    Embryonal rhabdomyosarcoma

  • □n

    Deep (aggressive) angiomyxoma

Angiomyofibroblastoma

Clinical Features

This is a benign neoplasm that occurs in the vulvovaginal region of reproductive-aged women but it may also occur in the inguinoscrotal region in males. It is often thought to represent a cyst on clinical examination.

Pathologic Features

Gross Findings

The tumors are typically small (usually <5 cm) and well circumscribed, and they display a tan/white and rubbery cut surface.

Microscopic Findings

Angiomyofibroblastoma, although not encapsulated, is well demarcated from the surrounding vulvar soft tissues. It is composed of plump, ovoid (plasmacytoid) to spindle-shaped cells that may be multinucleated and tend to cluster around the numerous small- to medium-caliber blood vessels. The cell clusters are set within a variably edematous to collagenous matrix with alternating zones of cellularity ( Fig. 4.3 ). Mitotic activity is uncommon and occasionally intratumoral adipose tissue may be present.

FIG. 4.3, Angiomyofibroblastoma. Alternating hypocellular and hypercellular areas are seen. Tumor cells tend to cluster around numerous capillary-sized vessels.

Ancillary Studies

Immunohistochemistry

The tumor cells are typically positive for desmin, ER, and PR. Smooth-muscle actin positivity is variable but usually negative. CD34 is typically negative and RB1 expression is typically intact.

Differential Diagnosis

The most important differential diagnostic consideration is the distinction of angiomyofibroblastoma from deep (aggressive) angiomyxoma because of the differences in biologic behavior and treatment. Unlike deep angiomyxoma, angiomyofibroblastoma is well circumscribed and has alternating zones of cellularity and more prominent vascularity composed of small- to medium-sized vessels, in contrast to the infiltrative growth, homogeneous hypocellularity and medium- to large-sized vessels typically seen in deep angiomyxoma. Other entities to consider in the differential diagnosis with angiomyofibroblastoma include fibroepithelial stromal polyp, cellular angiofibroma, mammary-type myofibroblastoma and prepubertal vulvar fibroma. Fibroepithelial stromal polyp is polypoid, has an ill-defined interface with surrounding tissue, a different vascular pattern (with centrally located larger vessels) and stellate and mutlinucleated cells near the stromal–epithelial interface. Cellular angiofibroma is more uniformly cellular, contains larger and more commonly hyalinized vessels, and is typically diffusely positive for CD34. Mammary-type myofibroblastoma is morphologically and immunohistochemically identical to myofibroblastoma of the breast and compared to angiomyofibroblastoma, it lacks the prominent vascular component and perivascular distribution of epithelioid cells. In addition, as cellular angiofibroma and mammary myofibroblastoma fall within a family of genetically related tumors showing loss of RB1/13q14 , there is typically loss of RB1 immunoexpression in these tumors. Finally, prepubertal vulvar fibroma is distinguished from angiomyofibroblastoma by occurring in a younger age group and by its ill-defined margins and patternless proliferation of bland spindle cells; in addition, it lacks the prominent vascular component and is CD34 positive.

Prognosis and Therapy

Angiomyofibroblastoma is a benign tumor without recurrent potential; therefore, local excision with clear margins is adequate treatment. Rarely, this tumor may undergo sarcomatous transformation.

Angiomyofibroblastoma—Fact Sheet

Definition

  • □n

    Tumor composed of myofibroblasts and thin-walled capillaries, which principally occurs in vulvovaginal soft tissues

Incidence and Location

  • □n

    Uncommon

  • □n

    Vulvovaginal region

Morbidity and Mortality

  • □n

    Benign, nonrecurring neoplasm

Gender and Age Distribution

  • □n

    Reproductive-aged women

Clinical Features

  • □n

    Often thought to represent a vulvar cyst

Prognosis and Treatment

  • □n

    Excellent prognosis

  • □n

    Local excision with clear margins

Angiomyofibroblastoma—Pathologic Features

Gross Findings

  • □n

    Usually <5 cm

  • □n

    Well circumscribed

  • □n

    Tan-white, rubbery cut surface

Microscopic Findings

  • □n

    Well circumscribed, non-encapsulated

  • □n

    Alternating zones of cellularity (cellular bundles alternating with edematous/fibrotic hypocellular areas)

  • □n

    Plump (plasmacytoid) to spindle-shaped cells

  • □n

    Numerous delicate thin-walled capillaries

  • □n

    Clustering of stromal cells around vasculature

  • □n

    Variably edematous to collagenous matrix

Immunohistochemical Features

  • □n

    Desmin, ER, PR typically positive

  • □n

    CD34 and smooth muscle actin typically negative

  • □n

    Intact RB1 expression

Differential Diagnosis

  • □n

    Deep “aggressive” angiomyxoma

  • □n

    Fibroepithelial stromal polyp

  • □n

    Cellular angiofibroma

  • □n

    Mammary-type myofibroblastoma

  • □n

    Prepubertal vulvar fibroma

Cellular Angiofibroma

Clinical Features

Cellular angiofibroma is a benign tumor that occurs in the vulva or perineum of middle-aged women (mean 54 years), although it also occurs in the inguinoscrotal region in men and at extragenital sites. In the vulva, they most commonly present as a small, well-circumscribed, painless, subcutaneous mass.

Pathologic Features

Gross Findings

Tumors are typically small (average 2.7 cm) with a well-demarcated border. On cut section, they have a firm, rubbery gray-white surface.

Microscopic Findings

Most cellular angiofibromas have a well-demarcated border on low-power examination; however, a few may exhibit focal limited infiltration of surrounding soft tissues. It is a cellular neoplasm composed of short, intersecting fascicles of bland spindle-shaped cells with scant pale-staining cytoplasm and ovoid nuclei ( Fig. 4.4 ). Scattered atypical nuclei or multinucleate cells may sometimes be seen. Rare examples of cellular angiofibroma have discrete foci of cytologically atypical cells or a sarcoma-like component, the latter as an abrupt transition to a discrete sarcomatoid component which in a subset closely resembles atypical lipomatous tumor or pleomorphic liposarcoma; the prognostic significance of these findings is uncertain. Mitoses are typically infrequent, but some tumors may show brisk mitotic activity. The vascular component is prominent with numerous, relatively homogeneous small- to medium-sized, thick-walled (and often hyalinized) blood vessels. Interspersed wispy collagen bundles are also characteristic and mast cells are a common associated finding. In addition, most tumors also have a small component of adipose tissue, often located at the periphery. Entrapped small nerves may also be seen at the periphery of the tumor.

FIG. 4.4, Cellular angiofibroma. Short intersecting fascicles of bland spindle-shaped cells and numerous small- to medium-sized vessels are present in a collagenous background.

Ancillary Studies

Immunohistochemistry

The tumor cells are positive for CD34 (in 60% of cases), smooth-muscle actin (20%), and desmin (8%). ER and PR may also be positive (∼50% of cases) whereas S-100 is negative. RB1 expression is deficient with loss of staining. In cases with sarcomatoid transformation having the appearance of a lipomatous tumor, MDM2 and CDK4 are negative, but p16 can be strongly positive.

Molecular Analysis

Cellular angiofibroma harbors monoallelic deletions of RB1 and FOXO1 at the 13q14 locus, a shared feature with spindle cell lipoma and mammary-type myofibroblastoma.

Differential Diagnosis

Because of the presence of short intersecting fascicles, cellular angiofibroma may be confused with a benign smooth-muscle tumor. It is distinguished from a leiomyoma by its shorter fascicles, more prominent vascular component, less abundant eosinophilic cytoplasm, and lack of blunt-ended nuclei. Mammary-type myofibroblastoma and cellular angiofibroma show significant morphologic and immunohistochemical overlap (although the vessels of the former are not as prominent), and based on their shared molecular abnormality, may be related tumors on a morphologic spectrum. Less frequently, cellular angiofibroma may be confused with angiomyofibroblastoma (discussed previously), prepubertal vulvar fibroma, deep angiomyxoma, and solitary fibrous tumor. Prepubertal vulvar fibroma occurs more commonly in young girls, has ill-defined margins, a hypocellular appearance, and patternless proliferation of spindle cells. Deep angiomyxoma more commonly involves deep soft tissue and has an infiltrative margin. In addition, it is myxoid and hypocellular, and RB1 immunoexpression is intact. In contrast to cellular angiofibroma, solitary fibrous tumor is characterized by a “patternless” architecture, heterogeneous cellularity, hemangiopericytoma-like vasculature, and frequent presence of keloid-type collagen; it is also typically positive for STAT6.

Prognosis and Therapy

Cellular angiofibroma is a benign tumor. Incomplete excision may lead to regrowth of tumor; therefore, local (conservative) excision with negative margins appears to be adequate treatment.

Cellular Angiofibroma—Fact Sheet

Definition

  • □n

    Tumor composed of bland spindle cells admixed with a prominent vascular component

Incidence and Location

  • □n

    Relatively uncommon; located in the vulvovaginal region (can occur at extragenital sites)

Morbidity and Mortality

  • □n

    Benign, nonrecurring tumor

Gender and Age Distribution

  • □n

    Middle-aged women (mean 54 years)

Clinical Features

  • □n

    Small, well-circumscribed subcutaneous mass

  • □n

    Patients may present with pain

Prognosis and Treatment

  • □n

    Local excision with clear margins

  • □n

    Excellent prognosis

Cellular Angiofibroma—Pathologic Features

Gross Findings

  • □n

    Typically small (<3 cm) and well circumscribed

  • □n

    Firm, rubbery consistency

  • □n

    Gray-white cut surface

Microscopic Findings

  • □n

    Usually well-demarcated border

  • □n

    Short intersecting fascicles of bland spindle-shaped cells

  • □n

    Cells with ovoid nuclei and scant, pale eosinophilic cytoplasm with indistinct borders

  • □n

    Typically no cytologic atypia but mitotic activity may be brisk; occasionally scattered atypical nuclei, zones of atypical cells, and rarely sarcomatous transformation

  • □n

    Prominent vascular component with small- to medium-sized vessels, often thick-walled and hyalinized

  • □n

    Interspersed wispy collagen bundles

  • □n

    Entrapped fat and nerves at the periphery

  • □n

    Abundant mast cells

Immunohistochemical Features

  • □n

    CD34 positive in 60%, smooth muscle actin in 20%, and desmin in 8% of cases

  • □n

    ER and PR positive in ∼50% of cases

  • □n

    RB1 loss of expression

  • □n

    S-100 negative

Differential Diagnosis

  • □n

    Leiomyoma

  • □n

    Mammary-type myofibroblastoma

  • □n

    Angiomyofibroblastoma

  • □n

    Prepubertal vulvar fibroma

  • □n

    Deep (aggressive) angiomyxoma

  • □n

    Solitary fibrous tumor

Mammary-Type Myofibroblastoma

Clinical Features

Mammary myofibroblastoma was first described in the breast with a predilection for older men; since its initial description, it is now known to occur in extramammary sites, particularly the inguinal/groin area and the term “mammary-type myofibroblastoma” is the designated terminology. In the largest series to date, this tumor more commonly affects males (66% vs. 34%) and anatomic locations include in order of frequency: inguinal/groin region, breast, chest wall/axilla, trunk, and extremities. The tumors occur in individuals over a wide age range (from first to tenth decade) with a mean age of 54 years. Most patients are asymptomatic but some present with a painless swelling or mass. Most tumors occurring in the groin are subcutaneous but it is important to note that outside this location, they may occasionally be deep-seated (intramuscular, pelvis, retroperitoneum, or abdomen).

Pathologic Features

Gross Findings

Mammary-type myofibroblastomas are usually pink or tan to brown, firm and well-circumscribed masses that often have a whorled, nodular, and occasionally mucoid cut section ( Fig. 4.5 ). Tumors can measure up to 22 cm with a mean size of 6.6 cm.

FIG. 4.5, Mammary-type myofibroblastoma. Well-demarcated mass with a homogeneous, vaguely nodular and tan cut surface.

Microscopic Findings

These tumors histologically resemble mammary myofibroblastoma. They are well-circumscribed, unencapsulated tumors composed of haphazardly arranged variably sized fascicles or a patternless proliferation of bland spindle cells with oval nuclei, pale cytoplasm, and indistinct cell borders ( Fig. 4.6 ). A variable amount of adipose tissue is present ranging from little/none to predominant ( Fig. 4.6 ). Stromal collagen can sometimes have a ropy appearance reminiscent of that seen in spindle cell lipoma. Less commonly, focal cytologic atypia often seen as “bizarre” degenerative appearing nuclei, epithelioid morphology, or neurilemmoma-type nuclear palisading can be seen.

FIG. 4.6, Mammary-type myofibroblastoma. Proliferation of bland spindle cells in a vaguely fascicular pattern. The tumor has varying amounts of benign adipose tissue.

Ancillary Studies

Immunohistochemistry

The spindle cells are frequently positive for desmin and CD34; only rare cases are negative for these markers. RB1 expression is lost in the vast majority (>90%).

Molecular Analysis

Mammary-type myofibroblastoma can show loss of 13q14 similar to cellular angiofibroma and spindle cell lipoma. As these tumors can also have significant morphologic and immunophenotypic overlap, it is thought that they likely represent a spectrum of neoplasia within a genetically related family of tumors.

Differential Diagnosis

The differential diagnosis includes cellular angiofibroma and angiomyofibroblastoma (discussed previously), prepubertal vulvar fibroma and deep (aggressive angiomyxoma). Prepubertal vulvar fibroma more commonly occurs at a younger age, is more infiltrative and less cellular, and lacks a fascicular growth. Deep (aggressive) angiomyxoma is uniformly myxoid and hypocellular, has infiltrative margins, lacks fascicular growth, and shows intact RB1 expression.

Prognosis and Therapy

Mammary-type myofibroblastoma is benign. There appears to be a very low risk of recurrence as there have been two documented recurrences 17 and 20 years after initial excision.

Mammary-Type Myofibroblastoma—Fact Sheet

Definition

  • □n

    Benign mesenchymal neoplasm composed of a patternless proliferation of spindle cells and variable amounts of adipose tissue, histologically resembling mammary myofibroblastoma

Incidence and Location

  • □n

    Uncommon

  • □n

    Inguinal/groin region>breast>chest wall/axilla>trunk>extremities

Morbidity and Mortality

  • □n

    Low risk of (often late) recurrence

Gender and Age Distribution

  • □n

    M>F

  • □n

    Wide range (mean 54 years)

Clinical Features

  • □n

    Most asymptomatic

  • □n

    Slow growing painless mass/swelling

Prognosis and Treatment

  • □n

    Local excision

  • □n

    Benign neoplasm with low risk of recurrence

Mammary-Type Myofibroblastoma—Pathologic Features

Gross Findings

  • □n

    Pink, tan-brown firm, well-circumscribed mass

  • □n

    Whorled, nodular, occasionally myxoid cut surface

  • □n

    Mean 6.6 cm

Microscopic Findings

  • □n

    Well circumscribed and unencapsulated

  • □n

    Haphazardly arranged fascicles or patternless growth

  • □n

    Bland spindle cells with ovoid nuclei and pale indistinct cytoplasm

  • □n

    Variable amounts of adipose tissue

  • □n

    Stromal hyalinization and/or myxoid change common; ropy collagen may be seen

  • □n

    Unusual features: focal cytologic atypia, epithelioid morphology, neurilemmoma-type appearance

Immunohistochemical Features

  • □n

    Desmin and CD34 frequently positive

  • □n

    RB1 loss of expression (>90%)

Differential Diagnosis

  • □n

    Cellular angiofibroma

  • □n

    Angiomyofibroblastoma

  • □n

    Prepubertal vulvar fibroma

  • □n

    Deep (aggressive) angiomyxoma

Prepubertal Vulvar Fibroma

Clinical Features

Prepubertal vulvar fibroma typically occurs in young girls (range 4–12 years) as a gradual vulvar swelling; it is typically unilateral, painless, and most commonly involves the labium majus.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here